Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Buying
Did a little digging. I like what I see. Missed SAVA when I saw it at 3 not doing that again
Perfect got in at 26
I think anywhere between 25-27 is a good entry price - data should be there in May (PD biomarkers and AD interim data)
Here is the deal..
The equity holders of Annovis
Truly believe they own a safe and
Effical treatment for CNS disease.
Perhaps even complete cure/reversal.
They don’t need to be educated as to the
Multi multi billion dollar valuation..
Dr Maria has sold a previous medical company , so she understands multiples of valuation and that resources equal time lines equals people’s lives..
But she also knows.. there are many forces at play.. the people who build nursing and memory care facilities are
Not looking for a safe treatment.. they are looking for residents..
The combo therapy of Anavex’s Blarcamesine to cessation imbalance and Annovis drug to clear nerve damage..
Should encourage the Heavens from each living Star..
Beeeeeeeuuuuuutiful..
My point is.. with success Annovis is headed to a multi billion valuation.. either through next round if funding or a despatate BP( Biogen) that has just failed brilliantly..
Biogen went up three times over 30 billion in market cap over positive news for adusamnrob..
$30 billion would equal a share price of
$150X30= $4500
You decide where to buy in ..
Sold? On what?
I’m sold. What’s a good PT to get into tmw I was thinking setting it for 26.50 see if I can start there and average as I go.
How soon are the results?
Meowww..
Thought I saw some canary feathers floating in the air during the interview..
Now she is ringing a bell..
Wow..
You can’t get too obvious in my book!
Ring it loud
Ring it proud
Ding Dong we gonna have
another spear to stick in the
side of Dementia.. Eff Dementia
Maria to ring the Closing Bell today!
https://finance.yahoo.com/news/annovis-bio-ring-closing-bell-180000724.html
I've sent the request, I think iHub has to approve it...
Great post
Come on!
Do I need to do anything?
thanks! I'd like to be added as a moderator with you please. I love this company, this is personal for me as my grandpa died from PD. I ll help you to maintain the board and we should also add some information on the header.
180M Market cap
Tiny Float 4.3M
40% insider ownership
Top scientific advisory board including Rudolph E. Tanzi
Phase IIa results in the coming weeks for AD (was already positive for PD) - has shown efficacy and cognitive improvement in 30 days only! CEO stated Phase III could be short if they show efficacy in 6 month period with early FDA approval possible!
Addressable market size in the 100Bs (PD - AD - AD/DS)
thanks for posting Trader..
Very nice interview posted May 6th, go to mark 12mn, Maria seems very confident (she is not blinded), I actually have never seen her smiling that much!
company corporate presentation https://irpages2.eqs.com/download/companies/annovis/Presentations/Annovis%20Presentation%20-%20January%202021.pdf
Annovis Bio Announces Positive Phase 2 Data - Interim Data Shows ANVS401 Improves Speed and Coordination in Parkinson's Patients
https://app.quotemedia.com/quotetools/newsStoryPopup.go?storyId=8302791689639429&topic=ANVS&symbology=null&cp=off&webmasterId=89940
a little action today..
perhaps a little word slippage into a very
high and apparently uncomfortable short position..
Webinar just started. Traded this from $19.50 to $47 but am out for now. Need to hear whether or not there is an offering coming.
1B is closer to $130/share
Congratulations Annovis! The real beauty of this flower has not begun to blossom.
Annovis still has the Biological Chemistry to release in April and the Alzheimers Data( both Interim and Chemical) and another 40 patients data.. wow.
Statistically when one includes prior clinical success, each data release is another lock down of efficacy ..
Very exciting to have so many confirmatory data releases on such a
strategically centered and well managed budget!
A proper valuation on the Auction Block with Big Pharma striking out (they need a sure thing) is well into the Billions..
Perhaps as high as $10 Billion right now..
( Biogen went for $30Billion MC runs three times with just the Hint of Efficacy and having Brain swelling as side effect!!)
With less than 10,000,000 shares outstanding a minimal target is $1 B or $100 per share.. nice start to the run!
Let the Capital Flow Annovis has earned it.
With A continuing safety profile , Annovis should also be considered for immediate access for death sentences Dementia sufferers.!
access
https://app.quotemedia.com/quotetools/newsStoryPopup.go?storyId=8302791689639429&topic=ANVS&symbology=null&cp=off&webmasterId=89940
No profits, High negative returns, was $2.41 less than a year ago,
insiders have a lot to dump, not saying will but why wouldn't after becoming worth many 100's of millions and own over 40% of the shares. Take profit/cut loses imho heck of a gap up too. Congrats to the longs.
Profitability
Profit Margin 0.00%
Operating Margin (ttm) 0.00%
Management Effectiveness
Return on Assets (ttm) -89.86%
Return on Equity (ttm) -180.82%
Balance Sheet
Total Cash (mrq) $8.07M
Total Cash Per Share (mrq) $1.16
Net Income Avi to Common (ttm) -5.46M
Cash Flow Statement
Operating Cash Flow (ttm) -3.97M
Levered Free Cash Flow (ttm) -3.02M
In the Statemkent showing efficacy with Pifitrin..
Annovis also said this, ""To date we have shown that ANVS401 fully recovers memory and learning in animals with Alzheimer's disease, Down syndrome and traumatic brain injury, fully recovers function in animals with Parkinson's disease and frontotemporal dementia, and recovers sight in rats with glaucoma. In this study we have found that our drug fully recovers cognition and function in stroke mice. Each successful study further supports our plans to move into late-stage studies of ANVS401."
Pretty damn exciting!
why would Annovis try adjunctive Therapy with Pifitrin?
Our results showed that post-injury administration of PFT-a and, particularly, PFT-a (O) at 5h dramatically reduced injury volumes in the ipsilateral hippocampus, improved motor outcomes, and ameliorated cognitive deficits at 7days after TBI, as evaluated by novel object recognition and open-field test. PFT-a and especially PFT-a (O) significantly reduced the number of FJC-positive cells in hippocampus CA1 and DG subregions, versus vehicle treatment, and significantly decreased caspase-3 and PUMA mRNA expression. PFT-a (O), but not PFT-a, treatment significantly lowered p53 and elevated SOD2 mRNA expression. Double immunofluorescence staining demonstrated that PFT-a (O) treatment decreased p53, annexin V and 4-HNE positive neurons in the hippocampal CA1 region. Furthermore, PUMA co-localization with the mitochondrial maker COX IV, and the upregulation of PUMA were inhibited by PFT-a (O) after TBI. Our data suggest that PFT-a and especially PFT-a (O) significantly reduce hippocampal neuronal degeneration, and ameliorate neurological and cognitive deficits in vivo via antiapoptotic and antioxidative properties.
looking at trading patterns..
that our CEO shared positive outlook of company Feb 16-18..
and earlier trade volume flow over from Cassava positive..
I would estimate there are at least 3,000,000 or more possibly as high
as 5,000,000 or more shares of Annovis sold SHORT..
Annovis only has a total of 7,000,000 shares outstanding..and I think the float offered for trading was around 3,000,000...
Insiders are not sellers....
so IF good news hits..even if ZERO new buyers come into OWN THE STOCK,
short covering will drive up valuation..(IMO) well past the $500,000,000 mark, probably through $1,000,000,000 Mark..even with Capital Raise offering a couple of million shares..that puts Stock around $100 per share or more..with a couple hundred million in the bank for confirmatory clinicals..
And IF the company is for sale...........which I believe, based upion CEO's track record of success, ANVS always will be..
the valuation will be well past $3 Billion...
so even at $100/share..
there will be tremendous upside..
Glad there are not
Well I sure hope so...and hopefully either this week or next
Marvy it’s a poker game . Never show your cards.
You never do an investor conference with bad news..
They went 4 for 4 in first in human clinical.
All in vitro Clinicals have been paititve.
The sick has gone from $6 to as high as $35 in around 1 month...
There are only maybe 3,000,000 shares in the float will trade before
News..
I like the signs that something very special is about to happen.
It was an investor conference correct? My guess is that they want an investor before dropping news...itll either be they will announce dilution before news or after news in the next 2 weeks
Still don’t know is Annovis has presented..
There is simply not this much trading stock at this price..
Short sellers buying back and forth with short sellers..
Wait until longs come
Back in the market.. that is when the fireworks happen..
Maxim as just raised Target Valuation of Cassava to almost $3 Billion!
granted Cassava does have AD test potential and is further along Clinical Trial Trail than Annovis..BUT..
A similar Target Valuation for Annovis of around $3 Billion ,
assuming a 25% increase in outstanding shares for Capital Raise,,
10 Million shares (after potential capital raise) $3 Billion MC
Equals $300 PS..that is MY 12 month Target Range..
Caveat Emptor.. I do not disclose buying or selling or positions..so as
always..DO YOUR OWN DUE DILLIGENCE, adn NEVER risk more than you may afford to lose..
annovis to present at Bio-CEO conference: here is link to register for presentation:
https://www.bio.org/events/bio-ceo-investor-digital-conference
its not free for Annovis shareholders..
I want to apologize for anything I get wrong as I am not a detail person and if I had to go back and verify every word of every post I would never post..so please do not base your investment decisions upon anything I post.
disappointed that Annovis chooses a conference to present data where common shareholders have to pay to learn about their Public Company.
I don't believe the Company may release any information not already known as that information would not be accessible to ALL shareholders simultaneously.
If memory serves me correctly:
We are currently awaiting data sets for 68 PD-54 and AD-14 patients in
a completed phase 2a..the data (IMO) will be conclusive that Annovis does indeed safely and therapeutically affect multiple CNS Targets within the CNS Nerve Cell(system) as Annovis and the World hoped.
This Data is estimated to be released in this Quarter by the Company's Own statements.
The reason WHY I believe the data set will come back positive IS the Company has filed a Shelf Registration for $250,000,000 for Capital Raise. They probably will not raise this much money off the news..but IF Stock goes to FAIR Valuation(Over $1 Billion) after good news..
I could see 2.5 million shares offered at $100 per share..
Maybe they will!
What is current FAIR valuation? well there are currently under 7,000,000 share outstanding, so at current price..Market is up today..
A strong Data Set release deserves at least a $500,000,000 valuation:
look at :Personally I think Fair is Over $1 Billion..
Annavex: $800 Million 60 million shares out
Cassava; $1.6 Billion 35 million shares out
AC Immune: $580 million 70 milllion million shares out
Annovis: $150 Million 7 million shares ( approx. Half in Trading Float)
Yu can see that ownership of Annovis Stock is not ONLY at a much Lower Market Cap Price, but shares are much harder to come by..(which in theory should extract a premium to market on good news)..
a $500,000,000 Target Price puts Annovis around $70 Per SHare..
currently the share price is around $25..
Maybe an attendee will be kind enough to post the transcript or Info from Conference on IHUB..consider it officially requested anyone..
Say what you want but this Doc gets Capitalism more than list Drs.
Like my investment even more.
..
here is a little more due diligence on our CEO.
https://medcitynews.com/2011/10/serial-entrepreneur-to-receive-award/
I looked up sale of Symphony Pharma..
If same company..sold for over $500,000,000...
I don't think I give enough credits to our Leadership Team..
just raised my Price Target..IF positive Trail Results are
extremely positive, leaving little doubt to Annovis Therapeutic value..
a reasonable value in THIS Market would be at least $1 Billion..AND keep in mind..our CEO has SOLD her previous efforts, so why would not she do so again? I think she would..why not? maybe for equity swap in larger Pharma..
But regardless..with success comes multi billion valuation..
with 7,000.000 outstanding that puts co well north of $100 Per Share..
however..there will probably be equity raise and dilution..BUT..
that will still add VALUE....Hard not to be very excited about potential of good news soon..
Never any sure things.. but Annovis looks like they believe they will be able to do a secondary offering.. soon..
The only way they do that is with good news..so we will see..
Hi I got in a week ago I’m happy and the prospects are obvious thanks for your input here $ANVS
In the public float there are perhaps 3,000,000 shares, my guess is many of those are held for very long term..
Until the next equity offering..
Shares of Annovis may be hard to come by..
from the 4 MCI Patients on Annovis website:
Proof of Concept Study
?
Annovis conducted an experiment in rats, where it is possible to measure the PK of ANVS401 in plasma, CSF and the brain. Annovis extrapolated human plasma/CSF and rat plasma/CSF/brain levels to calculate human brain levels of ANVS401 and determined they were eight times higher than plasma levels. This is consistent with the data the Company has in mice, where in several studies, ANVS401 brain levels were found to be approximately 6-8 times higher in the brain than in plasma.
ANVS401’s extended presence in the brain is matched by an extended effect, reducing levels of APP, tau and aSYN for the whole 12-hour period tested. The extended effect of ANVS401 in human brains was consistent with the preclinical data in rodent brains.
?:
The persistence of ANVS401 in the CSF and brain and the extended pharmacodynamic effect observed make ANVS401 a good candidate for once a day dosing. Extrapolated brain levels of ANVS401 at 60 mg four times a day are far in excess of levels required to down-regulate APP and aSYN. The doses of ANVS401 needed to lower the levels of neurotoxic proteins are similar for the toxic proteins, suggesting similar dosing in AD-DS, AD and PD. Annovis further compared levels of ANVS401 in the brains of mice that had shown improved memory, learning and colonic motility and calculated that the optimum brain levels are between 150 and 500 nM. Using three different extrapolation/comparisons the Company deduced that a daily dose of 5-6 mg should achieve desired brain levels in humans.
MCI patients were treated for 10 days and CSF and plasma were extracted over 12 hours before the first administration of ANVS401 and after the last administration of ANVS401. The levels of neurotoxic proteins decreased to levels similar to the average found in healthy, normal volunteers.
MCI patients also showed high levels of inflammatory factors and microglia activation factors in their CSF. ANVS-401 significantly lowered the levels of several inflammation factors in their CSF
Followers
|
45
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
365
|
Created
|
02/04/21
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |